REFERENCES
1. Gunes D, Karaca M, Durmus A, et al. Challenges in the clinical management of rare diseases and center-based multidisciplinary approach to creating solutions. Eur J Pediatr. 2025;184:281.
2. Dani KA, Murray LJ, Razvi S. Rare neurological diseases: a practical approach to management. Pract Neurol. 2013;13:219-27.
3. Shan Z, Ding L, Zhu C, Sun R, Hong W. Medical care of rare and undiagnosed diseases: prospects and challenges. Fundam Res. 2022;2:851-8.
4. Hamasaki MY, Machado MCC, Pinheiro da Silva F. Animal models of neuroinflammation secondary to acute insults originated outside the brain. J Neurosci Res. 2018;96:371-8.
5. Hong H, Kim BS, Im HI. Pathophysiological role of neuroinflammation in neurodegenerative diseases and psychiatric disorders. Int Neurourol J. 2016;20 Suppl 1:S2-7.
6. Gurda BL, Bradbury AM, Vite CH. Canine and feline models of human genetic diseases and their contributions to advancing clinical therapies. Yale J Biol Med. 2017;90:417-31.
7. Zhao H, Liu E, Zhang YQ. Dog models of human atherosclerotic cardiovascular diseases. Mamm Genome. 2023;34:262-9.
8. Karkamo V, Airas N, Lindén J, et al. Severe spontaneous atherosclerosis in two korat breed cats is comparable to human atherosclerosis. J Comp Pathol. 2021;188:52-61.
9. Hytönen MK, Arumilli M, Lappalainen AK, et al. Molecular characterization of three canine models of human rare bone diseases: Caffey, van den Ende-Gupta, and Raine Syndromes. PLoS Genet. 2016;12:e1006037.
10. Kol A, Arzi B, Athanasiou KA, et al. Companion animals: translational scientist’s new best friends. Sci Transl Med. 2015;7:308ps21.
11. Hoang DM, Pham PT, Bach TQ, et al. Stem cell-based therapy for human diseases. Signal Transduct Target Ther. 2022;7:272.
12. Graves SS, Storb R. Evolution of haematopoietic cell transplantation for canine blood disorders and a platform for solid organ transplantation. Vet Med Sci. 2021;7:2156-71.
13. Graves SS, Storb R. Developments and translational relevance for the canine haematopoietic cell transplantation preclinical model. Vet Comp Oncol. 2020;18:471-83.
14. Lupu M, Storb R. Five decades of progress in haematopoietic cell transplantation based on the preclinical canine model. Vet Comp Oncol. 2007;5:14-30.
15. Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med. 2019;4:22.
16. Voga M, Adamic N, Vengust M, Majdic G. Stem cells in veterinary medicine-current state and treatment options. Front Vet Sci. 2020;7:278.
17. Han X, Liao R, Li X, et al. Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies. Signal Transduct Target Ther. 2025;10:262.
18. Acosta SA, Tajiri N, Hoover J, Kaneko Y, Borlongan CV. Intravenous bone marrow stem cell grafts preferentially migrate to spleen and abrogate chronic inflammation in stroke. Stroke. 2015;46:2616-27.
19. Jung HS, Jeong SY, Yang J, et al. Neuroprotective effect of mesenchymal stem cell through complement component 3 downregulation after transient focal cerebral ischemia in mice. Neurosci Lett. 2016;633:227-34.
20. Ichiryu N, Fairchild PJ. Immune privilege of stem cells. In: Zavazava N, Editors. Embryonic Stem Cell Immunobiology. Humana Press, Totowa, NJ; 2013. pp. 1-16.
21. Uder C, Brückner S, Winkler S, Tautenhahn HM, Christ B. Mammalian MSC from selected species: features and applications. Cytometry A. 2018;93:32-49.
22. Fguirouche A, Naji Y, Guennouni M, et al. HLA-DRB1 and DQB1 allelic polymorphism and multiple sclerosis in a moroccan population. Curr Issues Mol Biol. 2025;47.
23. Kim W, Patsopoulos NA. Genetics and functional genomics of multiple sclerosis. Semin Immunopathol. 2022;44:63-79.
24. Capello E, Mancardi GL. Marburg type and Balò’s concentric sclerosis: rare and acute variants of multiple sclerosis. Neurol Sci. 2004;25 Suppl 4:S361-3.
25. Singer BA, Feng J, Chiong-Rivero H. Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption. J Neurol. 2024;271:3116-30.
26. Islam MA, Alam SS, Kundu S, et al. Mesenchymal stem cell therapy in multiple sclerosis: a systematic review and meta-analysis. J Clin Med. 2023;12:6311.
27. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010;67:1187-94.
28. Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012;11:150-6.
29. Petrou P, Kassis I, Levin N, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain. 2020;143:3574-88.
30. Windsor R, Stewart S, Huentelman M, Keller S, Khanna C. An early clinical phenotype of necrotizing meningoencephalitis in the Pug reveals similarities to multiple sclerosis in humans. Am J Vet Res. 2024;85.
31. Greer KA, Wong AK, Liu H, et al. Necrotizing meningoencephalitis of Pug dogs associates with dog leukocyte antigen class II and resembles acute variant forms of multiple sclerosis. Tissue Antigens. 2010;76:110-8.
32. Windsor R, Stewart S, Schmidt J, et al. A potential early clinical phenotype of necrotizing meningoencephalitis in genetically at-risk pug dogs. J Vet Intern Med. 2022;36:1382-9.
33. Windsor R, Stewart SD, Talboom J, et al. Leukocyte and cytokine variables in asymptomatic Pugs at genetic risk of necrotizing meningoencephalitis. J Vet Intern Med. 2021;35:2846-52.
34. Windsor RC, Stewart S, Cassano JM, et al. Intravenous allogeneic mesenchymal stromal cell therapy in 13 Pugs with presumptive early necrotizing meningoencephalitis. J Am Vet Med Assoc. 2025;263:1-10.
35. Ye Y, Murdock DJ, Chen C, Liedtke W, Knox CA. Epidemiology of myasthenia gravis in the United States. Front Neurol. 2024;15:1339167.
36. Mantegazza R, Cordiglieri C, Consonni A, Baggi F. Animal models of myasthenia gravis: utility and limitations. Int J Gen Med. 2016;9:53-64.
37. Zhang X, Zhang D, Zhang Y, Wang J, Lu J. Restoration of skeletal muscle function via mesenchymal stem cells: mechanistic insights and therapeutic advances in myasthenia gravis. Front Cell Dev Biol. 2025;13:1658062.
38. Shelton GD, Cardinet GH, Lindstrom JM. Canine and human myasthenia gravis autoantibodies recognize similar regions on the acetylcholine receptor. Neurology. 1988;38:1417-23.
39. Shelton GD. Acquired myasthenia gravis: what we have learned from experimental and spontaneous animal models. Vet Immunol Immunopathol. 1999;69:239-49.
40. Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019;32:771-6.
41. Nijs M, Van Damme P. The genetics of amyotrophic lateral sclerosis. Curr Opin Neurol. 2024;37:560-9.
42. Morata-Tarifa C, Azkona G, Glass J, Mazzini L, Sanchez-Pernaute R. Looking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis. NPJ Regen Med. 2021;6:20.
43. Awano T, Johnson GS, Wade CM, et al. Genome-wide association analysis reveals a SOD1 mutation in canine degenerative myelopathy that resembles amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2009;106:2794-9.
44. Zeng R, Coates JR, Johnson GC, et al. Breed distribution of SOD1 alleles previously associated with canine degenerative myelopathy. J Vet Intern Med. 2014;28:515-21.
45. Crisp MJ, Beckett J, Coates JR, Miller TM. Canine degenerative myelopathy: biochemical characterization of superoxide dismutase 1 in the first naturally occurring non-human amyotrophic lateral sclerosis model. Exp Neurol. 2013;248:1-9.
46. Malysz-Cymborska I, Golubczyk D, Kalkowski L, et al. Intra-arterial transplantation of stem cells in large animals as a minimally-invasive strategy for the treatment of disseminated neurodegeneration. Sci Rep. 2021;11:6581.
47. Gouveia D, Correia J, Cardoso A, et al. Intensive neurorehabilitation and allogeneic stem cells transplantation in canine degenerative myelopathy. Front Vet Sci. 2023;10:1192744.
48. Kornegay JN. The golden retriever model of Duchenne muscular dystrophy. Skelet Muscle. 2017;7:9.
49. Gaina G, Popa Gruianu A. Muscular dystrophy: experimental animal models and therapeutic approaches (review). Exp Ther Med. 2021;21:610.
50. Vieira NM, Valadares M, Zucconi E, et al. Human adipose-derived mesenchymal stromal cells injected systemically into GRMD dogs without immunosuppression are able to reach the host muscle and express human dystrophin. Cell Transplant. 2012;21:1407-17.
51. Kerkis I, Ambrosio CE, Kerkis A, et al. Early transplantation of human immature dental pulp stem cells from baby teeth to golden retriever muscular dystrophy (GRMD) dogs: Local or systemic? J Transl Med. 2008;6:35.
52. Li P, Cui K, Zhang B, et al. Transplantation of human umbilical cord-derived mesenchymal stems cells for the treatment of Becker muscular dystrophy in affected pedigree members. Int J Mol Med. 2015;35:1051-7.
53. Dai A, Baspinar O, Yeşilyurt A, et al. Efficacy of stem cell therapy in ambulatory and nonambulatory children with Duchenne muscular dystrophy - Phase I-II. Degener Neurol Neuromuscul Dis. 2018;8:63-77.
54. Sullivan J, Benítez A, Roth J, et al. A systematic literature review on the global epidemiology of Dravet syndrome and Lennox-Gastaut syndrome: prevalence, incidence, diagnosis, and mortality. Epilepsia. 2024;65:1240-63.
55. Strzelczyk A, Zuberi SM, Striano P, Rosenow F, Schubert-Bast S. The burden of illness in Lennox-Gastaut syndrome: a systematic literature review. Orphanet J Rare Dis. 2023;18:42.
57. Ramos-Fresnedo A, Perez-Vega C, Domingo RA, et al. Mesenchymal stem cell therapy for focal epilepsy: a systematic review of preclinical models and clinical studies. Epilepsia. 2022;63:1607-18.
58. Altalhi AS, Javaid MS, Jones NC, et al. Effects of cell therapy on seizures in animal models of epilepsy: systematic review and meta-analysis. Epilepsia. 2026;67:13-26.
59. Brunel HDSS, Villaroel CL, Dallago BSL, Pogue R, Malard PF. Retrospective study of mesenchymal stem cell therapy in dogs with neurological complications resulting from infection by canine distemper virus. Braz. J. Sci. 2022;1:73-81.
60. Bonkowsky JL, Nelson C, Kingston JL, Filloux FM, Mundorff MB, Srivastava R. The burden of inherited leukodystrophies in children. Neurology. 2010;75:718-25.
61. Mahdieh N, Soveizi M, Tavasoli AR, et al. Genetic testing of leukodystrophies unraveling extensive heterogeneity in a large cohort and report of five common diseases and 38 novel variants. Sci Rep. 2021;11:3231.
62. Ream MA, Lam WKK, Grosse SD, et al. Evidence and recommendation for infantile Krabbe Disease newborn screening. Pediatrics. 2025;155:e2024069152.
63. Rutherford HA, Hamilton N. Animal models of leukodystrophy: a new perspective for the development of therapies. FEBS J. 2019;286:4176-91.
64. Boucher A, Herrmann JL, Morand P, et al. Epidemiology of infectious encephalitis causes in 2016. Med Mal Infect. 2017;47:221-35.
65. Duerlund LS, Nielsen H, Bodilsen J. Current epidemiology of infectious encephalitis: a narrative review. Clin Microbiol Infect. 2025;31:515-21.
66. Zhao W, Zhou Y, Hu Y, et al. Predictors of mortality and poor outcome for patients with severe infectious encephalitis in the intensive care unit: a cross-sectional study. BMC Infect Dis. 2024;24:421.
67. Said S, Kang M. Viral encephalitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470162/. [Last accessed on 20 Apr 2026].
68. León-Moreno LC, Reza-Zaldívar EE, Hernández-Sapiéns MA, et al. Mesenchymal stem cell-based therapies in the post-acute neurological COVID syndrome: current landscape and opportunities. Biomolecules. 2023;14:8.
69. Bian P, Ye C, Zheng X, et al. Mesenchymal stem cells alleviate Japanese encephalitis virus-induced neuroinflammation and mortality. Stem Cell Res Ther. 2017;8:38.
70. Lempp C, Spitzbarth I, Puff C, et al. New aspects of the pathogenesis of canine distemper leukoencephalitis. Viruses. 2014;6:2571-601.
71. Rendon-Marin S, da Fontoura Budaszewski R, Canal CW, Ruiz-Saenz J. Tropism and molecular pathogenesis of canine distemper virus. Virol J. 2019;16:30.
72. Pinheiro LL, de Lima AR, Martins DM, et al. Mesenchymal stem cells in dogs with demyelinating leukoencephalitis as an experimental model of multiple sclerosis. Heliyon. 2019;5:e01857.
73. Gokalsing E, Ferrolho J, Gibson MS, Vilhena H, Anastácio S. Efficacy of GS-441524 for feline infectious peritonitis: a systematic review (2018-2024). Pathogens. 2025;14:717.
74. Wanakumjorn P, Kimura K, Castillo D, et al. Mesenchymal stem/stromal cell therapy improves immune recovery in a feline model of severe coronavirus infection. Stem Cells Transl Med. 2025;14:szaf025.
75. Mohamadian S, Kazerooni P, Taheri Mirghaed A, et al. ; Department of Clinical Science, Faculty of Veterinary Medicine, Urmia Branch, Islamic Azad University, Urmia, Iran. Successful treatment of feline infectious peritonitis disease (FIP) with mesenchymal stem cells. Iran J Vet Med. 2025;19:397-404.
76. Grech N, Dalli T, Mizzi S, Meilak L, Calleja N, Zrinzo A. Rising incidence of glioblastoma multiforme in a well-defined population. Cureus. 2020;12:e8195.
77. Nowak B, Rogujski P, Janowski M, Lukomska B, Andrzejewska A. Mesenchymal stem cells in glioblastoma therapy and progression: how one cell does it all. Biochim Biophys Acta Rev Cancer. 2021;1876:188582.
78. Herranz C, Fernández F, Martín-Ibáñez R, et al. Spontaneously arising canine glioma as a potential model for human glioma. J Comp Pathol. 2016;154:169-79.
79. Yost NM, Angelastro JM. Canine glioma as a model for human glioblastoma. In: Agrawal A, Singh Kunwar D, Editors. Glioblastoma-current evidence. IntechOpen, 2022.[DOI:10.5772/intechopen.106464].
80. Cloquell A, Mateo I, Gambera S, et al. Systemic cellular viroimmunotherapy for canine high-grade gliomas. J Immunother Cancer. 2022;10:gmr.15028310.
81. Villatoro AJ, Alcoholado C, Martín-Astorga MDC, et al. Suicide gene therapy by canine mesenchymal stem cell transduced with thymidine kinase in a u-87 glioblastoma murine model: secretory profile and antitumor activity. PLoS ONE. 2022;17:e0264001.
82. Zeira O, Asiag N, Aralla M, et al. Adult autologous mesenchymal stem cells for the treatment of suspected non-infectious inflammatory diseases of the canine central nervous system: safety, feasibility and preliminary clinical findings. J Neuroinflammation. 2015;12:181.
83. Gonçalves D, Gomes M, Guterra V, et al. Research article mesenchymal stem cell infusion for the treatment of neurological sequelae of canine distemper virus: a clinical study. Genet Mol Res. 2018;17:gmr18088.
84. Pinheiro AO, Cardoso MT, Vidane AS, et al. Controversial results of therapy with mesenchymal stem cells in the acute phase of canine distemper disease. Genet Mol Res. 2016;15:gmr.15028310.
85. Kim TY, Kim NH, Chae JA, et al. Evaluation of cognitive and mobility function in geriatric dogs following treatment with stem cell and stem cell extracellular vesicles derived from embryonic stem cells: a pilot study. Front Vet Sci. 2025;12:1549870.
86. Kim Y, Jo SH, Kim WH, Kweon OK. Antioxidant and anti-inflammatory effects of intravenously injected adipose derived mesenchymal stem cells in dogs with acute spinal cord injury. Stem Cell Res Ther. 2015;6:229.
87. Vikartovska Z, Kuricova M, Farbakova J, et al. Stem cell conditioned medium treatment for canine spinal cord injury: pilot feasibility study. Int J Mol Sci. 2020;21:5129.
88. Sharun K, Kumar R, Chandra V, et al. Percutaneous transplantation of allogenic bone marrow-derived mesenchymal stem cells for the management of paraplegia secondary to Hansen type I intervertebral disc herniation in a Beagle dog. Iran J Vet Res. 2021;22:161-6.
89. Orlandin JR, Gomes IDS, Sallum Leandro SF, et al. Treatment of chronic spinal cord injury in dogs using amniotic membrane-derived stem cells: preliminary results. Stem Cells Cloning. 2021;14:39-49.
90. Deng WS, Yang K, Liang B, Liu YF, Chen XY, Zhang S. Collagen/heparin sulfate scaffold combined with mesenchymal stem cells treatment for canines with spinal cord injury: a pilot feasibility study. J Orthop Surg. 2021;29:23094990211012293.
91. Steffen F, Smolders LA, Roentgen AM, Bertolo A, Stoyanov J. Bone marrow-derived mesenchymal stem cells as autologous therapy in dogs with naturally occurring intervertebral disc disease: feasibility, safety, and preliminary results. Tissue Eng Part C Methods. 2017;23:643-51.
92. Steffen F, Bertolo A, Affentranger R, Ferguson SJ, Stoyanov J. Treatment of naturally degenerated canine lumbosacral intervertebral discs with autologous mesenchymal stromal cells and collagen microcarriers: a prospective clinical study. Cell Transplant. 2019;28:201-11.
93. Bach FS, Rebelatto CLK, Fracaro L, et al. Comparison of the efficacy of surgical decompression alone and combined with canine adipose tissue-derived stem cell transplantation in dogs with acute thoracolumbar disk disease and spinal cord injury. Front Vet Sci. 2019;6:383.
